Aquestive Therapeutics, Inc.
AQST
$2.87
$0.020.70%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -110.27% | -465.55% | 52.61% | -259.00% | 34.33% |
| Total Depreciation and Amortization | -65.59% | -39.77% | -29.07% | -36.31% | -12.41% |
| Total Amortization of Deferred Charges | 50.11% | 4,430.51% | 4,423.73% | 4,673.21% | 3,000.00% |
| Total Other Non-Cash Items | 22.05% | 103.12% | 96.47% | 1,819.05% | 354.48% |
| Change in Net Operating Assets | 580.36% | -236.26% | -170.85% | -823.67% | -105.58% |
| Cash from Operations | -31.30% | -406.18% | 11.39% | -217.79% | -158.72% |
| Capital Expenditure | 6.25% | 47.02% | 95.76% | -1,350.00% | 38.46% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 6.25% | 47.02% | 95.76% | -1,350.00% | 38.46% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 99.99% | -60.00% | 99.86% | 99.94% | -- |
| Issuance of Common Stock | -95.35% | -96.13% | -77.78% | 8,921.72% | 297.36% |
| Repurchase of Common Stock | -- | -- | -66.67% | -11,062.50% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.06% | -- | -- | -- | 1,305.63% |
| Cash from Financing | -95.99% | -100.34% | -60.09% | 988.01% | 1,572.22% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -507.37% | -582.75% | -19.88% | 18,342.46% | -112.12% |